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Abstract. The aim of the present study was to determine the 
clinical significance of p53 and p21ras p21wafl, p27kip1 and p16ink4a 
expression in cases of early gastric cancer. A total of 81 patients 
who had undergone gastrectomy with D2 lymphadenectomy 
between 1971 and 2004 were retrospectively investigated. The 
immunohistochemical expression of p21ras, p53, p21waf1̸cip1, 
p27kip1 and p16ink4a in the tissues was evaluated. In normal, 
metaplastic and tumoral mucosa, p53 was positive in 53, 87.3, 
and 87.1% of the cases, respectively. In the same tissues, p21ras 
was positive in 85.3, 86 and 96.8%, respectively. Positivity 
for p16ink4a was detected in 46.3, 91.1 and 86% of the cases, 
respectively, whereas p27kip1 was positive in 60, 94.7 and 95.3%, 
and p21wafl/cip1 was positive in 32.4, 72.7 and 71.4% of the cases, 
respectively. All the tumors were positive for p53. Tumors with 
lymph node invasion presented with overexpression (+4) of p53 
in 47% of the cases vs. 17% of patients who did not have lymph 
node involvement. Therefore, higher expression of p53, p21ras 
and p21wafl/cip1 in the tumor exhibited a statistically significant 
association with lymph node involvement.
Introduction
The incidence and mortality rates of gastric cancer are high, 
mainly in Western countries, with an estimated 989,600 new 
gastric cancer cases and 738,000 deaths in 2008, accounting 
for 8% of the total cancer cases and 10% of total cancer-related 
deaths (1). Asia, Eastern Europe and South America are the 
principal regions of gastric cancer occurrence, which may 
be associated with dietary variables and the high prevalence 
of Helicobacter pylori (H. pylori) infection (2). However, the 
gastric carcinoma rates worldwide have decreased markedly (3).
The biology of gastric cancer is associated with the activity 
of several molecular markers, which are correlated with the risk 
of lymph node invasion and metastasis; among these markers, 
p21ras, p53, p21waf1/cip1, p27kip1 and p16ink4a currently appear to be 
inherently correlated with gastric cancer behavior (4-8). These 
markers are differentially expressed, depending on the gastric 
carcinoma type (9). Well-documented series of tumors with 
specific immunohistochemical antibodies reported an asso-
ciation between protein expression and clinical outcome (10). 
Patients with gastric cancer merely invading the mucosal space 
have a very low incidence of lymph node metastasis, whereas up 
to 20% of cases with submucosal invasion had nodal metastasis, 
requiring lymphadenectomy for complete disease removal (11). 
As the majority of reports have focused on invasive gastric 
cancer, the aim of the present study was to investigate a series 
of early gastric cancers and examine the expression of the p53, 
p16ink4a, p21waf1/cip1, p21ras and p27kip1̸cip1 proteins in normal, meta-
plastic and mucosal tumor tissues, and determine the positive 
and negative correlations with the risk of lymph node metas-
tasis in early gastric cancer patients with submucosal invasion 
submitted to gastrectomy with D2 lymphadenectomy.
Patients and methods
Patients. Cases were retrospectively assessed from the files 
of the Gastric Cancer Database of Hospital das Clínicas of 
the University of São Paulo School of Medicine (São Paulo, 
Brazil), between 1971 and 2004. Records from 1,989 patients 
with gastric cancer were selected. The inclusion criteria were 
as follows: Patients with primary gastric adenocarcinoma with 
submucosal invasion who had been submitted to gastrectomy 
with D2 lymphadenectomy, with at least 15 lymph nodes 
isolated from the surgical specimen. Patients with previous 
gastric surgery and gastric stump cancer were excluded. From 
the 120 patients with submucosal early gastric cancer (EGC), 
81 patients fulfilled the inclusion criteria for the present study. 
Representative areas of tumoral, normal and metaplastic 
mucosa were selected from new paraffin sections stained with 
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hematoxylin and eosin. The Manual Tissue Microarray kit 
(Beecher®, Sun Prairie, WI, USA) was used for removing the 
samples from the previously selected areas of the donor blocks 
and create new paraffin blocks of tissue microarrays (TMA).
The gastric carcinomas were classified according to the 
guidelines of the Japanese Gastric Cancer Association and 
Union for International Cancer Control (UICC, 1997) and histo-
logically classified according to the Lauren classification (12).
Immunohistochemical reactions. The TMA paraffin blocks 
were submitted to immunohistochemical examination for 
the following markers: p21ras (monoclonal mouse antibody; 
clone NCC‑RAS‑001, DakoCytomation M0637, Carpinteria, 
CA, USA), p21waf1/cip1 (monoclonal mouse antibody; clone 
SX118, DakoCytomation M7202, Glostrup, Denmark), p27kip1 
(monoclonal mouse antibody; clone SX53G8 DakoCytomation 
M7203), p16ink4a (monoclonal mouse antibody; clone E6H4 
DakoCytomation K5334), and p53 (monoclonal mouse antibody; 
clone DO-7 DakoCytomation, M7001). For positive reaction 
observation, 60 mg% 3,3'‑diaminobenzidine tetrahydrochloride 
(D‑5637, Sigma-Aldrich; Merck KGaA, USA), 1 ml dimethyl-
sulfoxide, 1 ml H2O2 6% and 100 ml phosphate-buffered saline 
were incubated for 5 min at 37˚C in the dark. The specific details 
of the immunohistochemical reactions are presented in Table I. 
Positive controls for the anti-p21ras, anti-p21waf1/cip1 and anti-p27kip1 
antibodies were normal palatine tonsyl. For the anti‑p53 anti-
body, the positive control was pulmonary adenocarcinoma. 
High-grade cervical intraepithelial neoplasia was used as control 
for anti-p16ink4a. Nuclear brown staining was considered as a 
positive reaction for p53, p21waf1/cip1 and p27kip1; for p21ras, cyto-
plasmic staining alone was considered as a positive reaction; and 
for p16ink4a, cytoplasmic or nuclear staining was accepted as a 
positive reaction. The negative control was obtained without the 
primary antibody incubation stage. The positive immunoreac-
tion quantification was as follows: The samples were quantified 
in 5 categories: 0, no cells stained; 1+, ≤10% positive cells; 2+, 
11‑25% positive cells; 3+, 26‑50% positive cells; and 4+, >51% 
positive cells. The significance of each category was correlated 
with the pathological variables, avoiding establishing an arbi-
trary cut-off point. The association analysis between the clinical 
data and marker positivity was performed using the Chi-squared 
test. The level of significance was set at 5% (α=0.05).
Positive controls for the anti-p21ras, anti-p21wafl/cip1 and 
anti-p27kip1 antibodies, were normal amygdale. For the anti‑p53 
antibody, the positive control was pulmonary adenocarcinoma. 
High-grade cervical intraepithelial neoplasia was used as 
control for anti-p16ink4a.
Nuclear brown staining was considered as a positive 
reaction for p53, p21waf1/cip1 and p27kip1; for p21ras, cytoplasmic 
staining alone was considered as a positive reaction; and for 
p16ink4a, cytoplasmic or nuclear staining was accepted as a 
positive reaction. The negative control was obtained without 
the primary antibody incubation stage.
Positive immunoreaction quantification. The samples were 
quantified in five categories: 0, no cells stained; 1+, ≤10% posi-
tive cells; 2+, 11‑25% positive cells; 3+, 26‑50% positive cells; 
and 4+, >51% positive cells. The significance of each category 
was correlated with the pathological variables, avoiding estab-
lishing an arbitrary cut-off point. The association analysis 
between the clinical data and marker positivity was performed 
using the Chi‑squared test. The level of significance was set at 
5% (α=0.05).
Results
Patient characteristics. A total of 81 complete cases were 
obtained, including tumoral, normal and metaplastic mucosa. 
There was lymph node invasion in 11 patients (13.6%). It was 
not possible to recover the lymph node samples with cancer 
invasion from the paraffin blocks in 8 cases. The epidemio-
logical and clinical characteristics of the patients are listed in 
Table II. There were no significant differences between 
the tumor markers and patient sex (Pearson's Chi‑squared 
test = 2.06 and P=0.55). There was no significant association 
between recurrence and expression of the markers (Pearson's 
Chi-squared test = 0.76 and P=0.99). The intestinal type 
was the most common according to the Lauren classifica-
tion (45 patients, 55.5%). The diffuse type was observed in 
25 (30.9%) patients and the mixed type in 11 (13.5%) patients.
Immunohistochemical reactions. All the immunohisto-
chemical reactions are summarized in Table III. Intestinal 
type tumors did not express p21waf1 in 29.4% of the cases. In 
67.6% of the samples, an intermediate positivity (<25% of 
the cells stained) was observed. In only 2.9% of the cases 
there was overexpression (>25% of positive cells). Among the 
diffuse type tumors, there was no expression of p21waf1/cip in 
40% of the cases; intermediate positivity was observed in 45% 
and overexpression in 15% of the cases. Mixed tumors were 
all positive for p21waf1/cip1 staining; however, 77.8% exhibited 
intermediate positivity and 22.2% exhibited overexpression. 
(Pearson's Chi‑squared test = 16.6 and P=0.034).
Positive reaction for p21ras was observed in the normal 
mucosa in 81.1% of the Lauren intestinal type tumors, followed 
by 86.4% of the diffuse type and 100% of the mixed type. 
A statistically significant difference was observed among the 
three histological types (Pearson's Chi‑squared test = 9.54 
and P=0.048). p27kip1 was positive in all cases with diffuse 
and mixed tumor types. A total of 8.8% of the intestinal type 
patients did not exhibit p27kip1 expression. Higher immuno-
histochemical expression of p27kip1 in the tumor was noted 
in 66.6, 50 and 33.3% of the diffuse, intestinal and mixed 
type tumors, respectively. Statistically significant differences 
were observed among the three histological types (Pearson's 
Chi‑squared test = 16.29 and P=0.038). A total of 34 (42%) 
patients exhibited invasion limited to the superficial part of the 
submucosal layer (Sm1) and 47 (58%) had invasion to a depth 
of >0.5 mm (Sm2). Among the markers, there was a higher 
positivity only for p27kip1 in the normal mucosa adjacent to 
Sm1 tumors (Pearson's Chi‑squared test = 12.81 and P=0.012).
Perineural invasion occurred in 5 (6.17%) cases. A greater 
overexpression of p16ink4a was observed in normal mucosa 
in cases with perineural invasion (Pearson's Chi‑squared 
test = 13.42 and P=0.009). Vascular invasion was observed in 
4 (4.9%) cases. There was a statistically significant correlation 
between positivity for p16ink4a in normal mucosa and vascular 
invasion (Pearson's Chi‑squared test = 33.42 and P<0,001).
Lymphovascular invasion was observed in 16 cases (19.7%). 
A total of 19 (23.4%) patients exhibited lymph node metastasis 
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from adenocarcinoma, of whom 4 (21%) exhibited Sm2 submu-
cosal invasion and 15 (78.9%) Sm1 type invasion. According to 
the Lauren classification, 10 (52.6%) were intestinal, 7 (36.8%) 
were diffuse and 2 (10.5%) were mixed type.
There was a correlation between the higher expression of 
p53 in the tumor and the presence of lymph node involvement 
(Pearson's Chi‑squared test = 8.18 and P=0.042). Patients with 
lymph node involvement also exhibited a higher expression of 
p21waf1/cip1 (Pearson's Chi‑squared test = 15.86 and P=0.003). 
Lymph node invasion was correlated with positive expression 
of p21ras (Pearson's Chi‑squared test = 9.533 and P=0.023), but 
not of p16ink4a (Pearson's Chi‑squared test = 1.27 and P=0.86) 
or p27kip1 (Pearson's Chi‑squared test = 2.55 and P=0.63). All 
the markers were significantly enhanced when the tumor was 
compared with normal mucosa. Comparison of normal and 
metaplastic mucosa revealed an increased expression of p53, 
p21waf1/cip1 and p27kip1, but not p16Ink4a and p21ras. The compar-
ison of metaplastic and tumoral mucosa revealed increased 
expression of p21ras in cancer cells.
Discussion
The results herein observed endorse, in part, the data avail-
able in the literature. Despite the excellent prognosis of 
early gastric adenocarcinoma when there is no lymph node 
metastasis, the majority of the markers correlated with cancer 
aggressiveness are associated with early stages of carcinoma 
invasion. Studies using immunohistochemical markers have 
the limitation inherent to the semi‑quantification of the posi-
tive reactions (5-7).
There is robust experimental evidence that genetic 
alterations and risk factors differ according to the histological 
type (13). Our results revealed significant differences between 
neoplastic and non-neoplastic protein expression, which 
corroborate, in part, the evidence observed in experimental 
settings. Normal mucosa exhibited p21ras positivity in 81.1% of 
the patients with intestinal type carcinoma, 86.4% with diffuse 
type, and 100% with mixed type, as previously reported (14). 
The prognostic value of p21ras in intestinal type carcinomas 
remains disputable (15).
Table I. Summary of the immunohistochemical procedures utilized in the study.
Antibody Clone Dilution Antigen retrieval  Source
p21ras NCC-RAS-001 1:100 Pressure cooker: Citric acid  DakoCytomation M0637,
   10 mM, pH 6.0, 3' and 30' Carpinteria, CA, USA
p21waf1/cip1 SX118 1:100 Pressure cooker: Tris-EDTA  DakoCytomation M7202,
   1 mM, pH 8.0, 2' and 30' Glostrup, Denmark
p27kip1 SX53G8 1:400 Pressure cooker: Tris‑EDTA  DakoCytomation M7203,
   1 mM, pH 8.0, 2' and 30' Glostrup, Denmark
p16ink4a E6H4 1:400 Pressure cooker: Citric acid  DakoCytomation K5334, 
   10 mM, pH 6.0, 3' and 30' Glostrup, Denmark
p53 DO‑7 1:200 Pressure cooker: Citric acid  DakoCytomation, M7001,
   10 mM, pH 6.0, 3' and 30' Glostrup, Denmark
EDTA, ethylenediaminetetraacetic acid.
Table II. Clinical characteristics of patients with early gastric 
carcinoma (n=81).
Characteristics No. (%)
Sex
  Female 31 (38.3)
  Male 50 (61.7)
Ethnic groups
  Caucasian 59 (72.2)
  Asian 7 (8.6)
  Afro‑Brazilian 14 (17.3)
  Others 1 (1.2)
Mean age, years ± SD 61.5±12.5
Median age, years ± SD 62±15.8
Familial history of gastric cancer  12 (14.8)
Main symptom
  Dyspepsia 58 (71.6)
  Asymptomatic 18 (22.2)
  Upper digestive bleeding 5 (6.2)
Hospital mortality (<30 days) 5 (6.2)
  Brain stroke 1 (1.2)
  Sepsis 2 (2.5)
  Respiratory complications 2 (2.5)
Follow‑up mortality (>30 days) 2 (2.5)
  Pleural metastasis 1 (1.25)
  Pulmonary metastasis 1 (1.25)
Histological type (Lauren)
  Intestinal 45 (55.5)
  Diffuse 25 (30.8)
  Mixed 11 (13.5)
Mean number of removed lymph nodes 32
Involved lymph nodes 19 (23.4)
Mean follow-up time, months 88
SD, standard deviation.
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Hyperexpression of p21waf1/cip1 was observed in diffuse and 
mixed type tumors, and the diffuse type included more cases 
with loss of expression of p21waf1/cip1. These results were quite 
different from other studies that did not observe differences in 
p21waf1̸cip1 expression among the histological types of gastric 
carcinoma (16-18). The incidence of lymph node metastasis 
is considered to be relatively higher in tumors with a superfi-
cially spreading growth pattern compared with the vertically 
infiltrating type, and the expression of p21waf1/cip1 was lower in 
the superficial spreading tumors (19).
However, we observed a strong positivity for p27kip1 in all 
tumors and a greater positivity in the diffuse type cases, as 
previously reported (4-6,14). The statistical analysis revealed 
greater positivity in the expression of p27kip1 in normal mucosa 
adjacent to Sm1 tumors. Although there was expression of 
p27kip1 in normal mucosa of Sm2 cases, there were fewer posi-
tive cells. We observed a progressive increase in the expression 
of p27kip1 in normal, metaplasic and tumoral mucosa. H. pylori 
infection was found to induce AKT/PI3K‑mediated phosphor-
ylation of p27, leading to cytoplasmic p27 mislocalization in 
gastric cancer, which is an adverse prognostic feature in gastric 
cancer. This is important, as p27 has both tumor-suppressive 
and oncogenic properties related to its subcellular localization. 
Cytoplasmic mislocalization of p27 induced by H. pylori may 
be an important mechanistic link between H. pylori infection 
and gastric carcinogenesis (20).
An association between hyperexpression of p16ink4a in normal 
mucosa and perineural and vascular invasion was observed. 
Similar results were not reported in the literature (8,14). 
However, there was no correlation between increased expres-
sion of p16ink4a (and p27Kip1) and lymph node invasion. Lymph 
node involvement was more frequent in p21ras-positive cases 
(P=0.023); inversely, cases with negative p21ras expression in 
the tumoral mucosa, did not exhibit lymph node metastasis. 
However, this result contradicts the findings of Kim et al (21), 
who did not identify a significant correlation between p21ras 
positivity and lymph node metastasis in advanced gastric 
cancer. p21ras positivity was not exclusively identified in tumor 
tissues, but was also described in non-neoplastic and normal 
tissues (22). The expression of p21ras is generally augmented 
in gastric adenocarcinoma and may be associated with worse 
prognosis. The correlation between lymph node invasion and 
hyperexpression of p21ras may be useful for selecting therapeutic 
alternatives for patients with p21ras-negative tumors (23,24).
A significant increase in the incidence of lymph node inva-
sion was observed in cases with marked immunohistochemical 
positivity for p53 in tumor samples (P=0.042), as previously 
documented (4,5).
Lymph node involvement was also statistically related to 
tumor cell positivity for p21waf1. None of the gastric carci-
nomas with negative immunoreaction for p21waf1 exhibited 
lymph node metastasis, and there was a higher frequency of 
lymph node involvement in cases with greater positivity for 
p21waf1, as previously documented (17,25). It was observed that 
65.4% of the cases were positive for p21waf1, and a higher inci-
dence of lymph node involvement was also found in patients 
with increased proliferative activity and loss of expression of 
p21waf1 in tumor tissue (26). The loss of p21waf1 expression and 
the relapse and mortality rates of gastric cancer indicate that 
the expression of p21waf1 is of prognostic value (25-27). Despite 
strong evidence supporting the role of p21waf1 as a prognostic 
marker, this finding remains debatable (28).
There was no correlation observed between the expres-
sion of p27kip1 in the tumor and the presence of lymph node 
involvement in advanced cancer cases (29). We did not identify 
a statistical correlation between the presence of lymph node 
involvement and the immunohistochemical expression of 
p16ink4a. This is a conflicting result compared with previous 
reports (30,31). Although the expression of p16ink4a is altered 
in gastric tumors, this alteration is considered to be secondary 
to p53 mutations (5). In normal mucosa, the expression of 
p16ink4a has been reported to be low (32). In gastric tumors, the 
p16ink4a expression is expected to be increased in intestinal and 
diffuse type tumors, but no significant difference in patients' 
life expectancy was reported (32).
The p16 protein was expressed in >95% of the normal 
gastric mucosa, 92% of dysplastic gastric mucosa and in 
almost 45% of gastric carcinoma samples (32). In addition, the 
expression of p16 in carcinoma metastatic to the lymph nodes 
was significantly reduced compared with the expression in the 
primary tumor (32).
A gradual decrease of p21waf1, p27kip1 and p16ink4a immu-
noreactions was expected from the normal to metaplastic and 
tumor tissue; however, increased rates of immune positive reac-
tions for all markers were observed. It was hypothesized that, 
in the early stages of cancer development, these mechanisms 
of cell regulation remain functional and, eventually become 
overexpressed in an attempt to prevent abnormal cellular 
proliferation. The progressive increase of the positivity for the 
protein markers in normal, metaplastic and tumoral mucosa 
occurred in parallel to the increase of the expression of p21ras 
(which stimulates cell division), as well as p53 (which reflects 
the loss of the main pathway of cell maintenance control), the 
most commonly affected by mutations (33). The increased p53 
expression detected by immunohistochemistry is frequently 
indicative of mutations in the p53 gene (34). This rationale may 
apply to p21ras as well, since mutations are present in ~15% of 
the tumors, and, specifically in gastric cancer, direct mutations 
of p21ras are less frequent (35,36). Mutations of the p16 gene 
in gastric cancer, however, appear to be uncommon, and the 
decrease in the expression of this protein in gastric cancer is 
considered to be secondary to other, still unknown mecha-
nisms (37). Additionally, mutations of the p27kip1 and p21waf1 
genes are also reported to be infrequent (38). The increased 
expression of these markers in early tumors is hypothesized 
to be an indirect consequence of an unknown mutation and̸or 
abnormal mechanism of controlling cell division.
In summary, the analysis of the clinical characteristics 
and the immune expression of p53, p21ras, p27kip1, p21waf1 and 
p16ink4a in patients with early gastric adenocarcinoma with 
submucosal invasion led to the conclusion that there is an 
important increase in the immunohistochemical expression of 
p53, p21ras, p27kip1, p21waf1/cip1 and p16ink4a when normal tissue is 
compared with neoplastic parenchyma. There is also a positive 
correlation between higher tumor expression of p21ras, p53 and 
p21waf1/cip1 and the presence of lymph node metastases, which 
was not observed for p27kip1 and p16ink4a. Finally, tumors with 
Sm1 invasion exhibited a higher positivity for p21waf1/cip1, whilst 
overexpression of p16ink4a in the normal mucosa was associated 
with perineural and vascular invasion.
MORON et al:  SUPPRESSOR ONCOGENES IN GASTRIC CANCER482
References
 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and 
Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 
87-108, 2012.
 2. Wroblewski LE, PeekRM Jr and Wilson KT: Helicobacter pylori 
and gastric cancer: Factors that modulate disease risk. Clin 
Microbiol Rev 23: 713‑739, 2010.
 3. Buckland G, Agudo A, Luján L, Jakszyn P, Bueno-de-Mesquita HB, 
Palli D, Boeing H, Carneiro F, Krogh V, Sacerdote C, et al: 
Adherence to a Mediterranean diet and risk of gastric adeno-
carcinoma within the European Prospective Investigation into 
Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr 91: 
381‑390, 2010.
 4. Liu XP, Kawauchi S, Oga A, Suehiro Y, Tsushimi K, Tsushimi M 
and Sasaki K: Combined examination of p27 (Kip1), p21 
(Waf1̸Cip1) and p53 expression allows precise estimation of 
prognosis in patients with gastric carcinoma. Histopathology 39: 
603‑610, 2001.
 5. Al-Moundhri MS, Nirmala V, Al-Hadabi I, Al-Mawaly K, 
Burney I, Al-Nabhani M, Thomas V, Ganguly SS and Grant C: 
The prognostic significance of p53, p27 kip1, p21 waf1, 
HER‑2/neu and Ki67 proteins expression in gastric cancer: A 
clinicopathological and immunohistochemical study of 121 Arab 
patients. J Surg Oncol 91: 243‑252, 2005.
 6. Gamboa-Dominguez A, Seidl S, Reyes-Gutier rez E, 
Hermannstädter C, Quintanilla‑Martinez L, Busch R, Höfler H, 
Fend F and Luber B: Prognostic significance of p21WAF1/CIP1, 
p27Kip1, p53 and E‑cadherin expression in gastric cancer. J Clin 
Pathol 60: 756‑761, 2007.
 7. Alves MK, Ferrasi AC, Lima VP, Ferreira MV, de Moura Campos 
Pardini MI and Rabenhorst SH: Inactivation of COX-2, HMLH1 
and CDKN2A gene by promoter methylation in gastric cancer: 
Relationship with histological subtype, tumor location and 
Helicobacter pylori genotype. Pathobiology 78: 266-276, 2011.
 8. Wang P, Mei J, Zhang N, Tao J, Tian H and Fu GH. Helicobacter 
pylori upregulates the expression of p16 (INK4) in gastric cancer 
cells. Hepatogastroenterology 58: 846‑853, 2011.
 9. Begnami MD, Fregnani JH, Brentani H, Torres C, Costa WL 
Jr, Montagnini A, Nonogaki S and Soares FA: Identification of 
protein expression signatures in gastric carcinomas using clus-
tering analysis: J Gastroenterol Hepatol 27: 378‑384, 2012.
10. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, 
Montagnini AL, da Costa WL Jr and Soares FA: Prognostic 
implications of altered human epidermal growth factor receptors 
(HERs) in gastric carcinomas: HER2 and HER3 are predictors 
of poor outcome: J Clin Oncol 29: 3030‑3036, 2011.
11. Lim MS, Lee HW, Im H, Kim BS, Lee MY, Jeon JY, Yang DH 
and Lee BH. Predictable factors for lymph node metastasis in 
early gastric cancer-analysis of single institutional experience: 
J Gastrointest Surg 15: 1783‑1788, 2011.
12. Lauren P. The two histological main types of gastric carcinoma: 
Diffuse and so-called intestinal type carcinoma. An attempt at 
a histo‑clinical classification. Acta Pathol Microbiol Scand 64: 
31‑49, 1965.
13. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, 
Fukamachi H, Jonkers J, Tanaka H, Eishi Y and Yuasa Y: 
Synergistic tumour suppressor activity of E‑cadherin and p53 
in a conditional mouse model for metastatic diffuse-type gastric 
cancer. Gut 61: 344‑353, 2012.
14. Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, 
D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G, et al: 
Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, 
p53, p16 (INK4A), p27 (KIP1), p21 (WAF1), Ki‑67 expression 
patterns in gastric cancer. J Cell Physiol 210: 183‑191, 2007.
15. Kasper HU, Schneider-Stock R, Mellin W and Roessner A: P21 
protein expression and ras-oncogene mutations in gastric carcinoma: 
Correlation with clinical data. Int J Oncol 12: 69-74, 1998.
16. Teh M and Lee YS. An immunohistochemical study of ras onco-
protein expression in gastric carcinoma: Cancer 72: 1846-1848, 
1993.
17. Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, 
Shimamoto F and Tahara E: Expression of cyclin-dependent 
kinase inhibitor p21WAF1/CIP1 in non‑neoplastic mucosa and 
neoplasia of the stomach: Relationship with p53 status and prolif-
erative activity. J Pathol 180: 122-128, 1996.
18. Jang SJ, Park YW, Park MH, Lee JD, Lee YY, Jung TJ, Kim IS, 
Choi IY, Ki M, Choi BY and Ahn MJ: Expression of cell-cycle 
regulators, cyclin E and p21WAF1/CIP1, potential prognostic 
markers for gastric cancer. Eur J Surg Oncol 25: 157‑163, 1999.
19. Ichinoe M, Mitomi H, Kikuchi S, Tanabe S, Akino F and Okayasu I: 
Mucosal high apoptotic activity and low p21WAF1̸CIP1 
expression and submucosal low proliferative activity in super-
ficially spreading early gastric cancers: Comparison with the 
penetrating growth type. Pathol Int 53: 81‑89, 2003.
20. Wen S, So Y, Singh K, Slingerland JM, Resnick MB, Zhang S, 
Ruiz V and Moss SF: Promotion of cytoplasmic mislocalization 
of p27 by Helicobacter pylori in gastric cancer: Oncogene 31: 
1771-1780, 2011.
21. Kim DH, Lee HI, Nam ES, Shin HS, Sohn JH, Park CH, Yoon DS, 
Song SY and Park YE: Reduced expression of the cell-cycle 
inhibitor p27Kip1 is associated with progression and lymph node 
metastasis of gastric carcinoma. Histopathology 36: 245‑251, 2000. 
22. Chesa PG, Rettig WJ, Melamed MR, Old LJ and Niman HL: 
Expression of p21ras in normal and malignant human tissues: 
Lack of association with proliferation and malignancy. Proc Natl 
Acad Sci USA 84: 3234‑3238, 1987.
23. Mita H, Toyota M, Aoki F, Akashi H, Maruyama R, Sasaki Y, 
Suzuki H, Idogawa M, Kashima L, Yanagihara K, et al: A novel 
method, digital genome scanning detects KRAS gene amplifi-
cation in gastric cancers: Involvement of overexpressed wild-type 
KRAS in downstream signaling and cancer cell growth. BMC 
Cancer 9: 198, 2009.
24. Kubota E, Kataoka H, Aoyama M, Mizoshita T, Mori Y, 
Shimura T, Tanaka M, Sasaki M, Takahashi S, Asai K and Joh T: 
Role of ES cell-expressed Ras (ERas) in tumorigenicity of gastric 
cancer. Am J Pathol 177: 955‑963, 2010.
25. Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T and 
Sugimachi K: Increased proliferative activity caused by loss 
of p21 (WAF1/CIP1) expression and its clinical significance 
in patients with early-stage gastric carcinoma. Cancer 94: 
2107-2112, 2002.
26. Ogawa M, Maeda K, Onoda N, Chung YS and Sowa M: Loss of 
p21WAF1/CIP1 expression correlates with disease progression in 
gastric carcinoma. Br J Cancer 75: 1617‑1620, 1997.
27. Jang SJ, Ahn MJ, Paik SS, Kong G, Keum JS, Park YW and 
Lee JD: Expression of cyclin dependent kinase inhibitor p21WAF1 
alone and in combination with p27KIP1 shows prognostic value 
in gastric carcinoma. J Korean Med Sci 13: 369‑376, 1998.
28. Kaye PV, Radebold K, Isaacs S and Dent DM. Expression of p53 
and p21waf1/cip1 in astric carcinoma: Lack of inter‑relationship 
or correlation with prognosis. Eur J Surg Oncol 26: 39‑43, 2000. 
29. Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, 
Mencarelli R, Segato P and Lise M: Low level of p27 (Kip1) protein 
expression in gastric adenocarcinoma is associated with disease 
progression and poor outcome. J Surg Oncol 81: 167‑175, 2002.
30. Kishimoto I, Mitomi H, Ohkura Y, Kanazawa H, Fukui N and 
Watanabe M: Abnormal expression of p16 (INK4a), cyclin D1, 
cyclin-dependent kinase 4 and retinoblastoma protein in gastric 
carcinomas. J Surg Oncol 98: 60-66, 2008.
31. Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, 
D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G, et al: 
Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, 
p53, p16 (INK4A), p27 (KIP1), p21 (WAF1), Ki‑67 expression 
patterns in gastric cancer. J Cell Physiol 210: 183‑191, 2007.
32. He XS, Su Q, Chen ZC, He XT, Long ZF, Ling H and Zhang LR: 
Expression, deletion and mutation of p16 gene in human gastric 
cancer. World J Gastroenterol 7: 515‑521, 2001.
33. Fenoglio-Preiser Cm, Wang J, Stemmermann Gn and 
Noffsinger A. TP53 and Gastric Carcinoma: A Review. Hum 
Mutat 21: 258‑270, 2003.
34. Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T and 
Sugimachi K. Growth pattern and expressions of cell cycle 
regulator proteins p53 and p21waf1/cip1 in early gastric 
carcinoma. Cancer 92: 1828‑1835, 2001.
35. Yasui W, Akama Y, Kuniyasu H, Yokozaki H, Semba S, 
Shimamoto F and Tahara E: Expression of cyclin-dependent 
kinase inhibitor p2lWAFI/CIP1 in non‑neoplasic mucosa and 
neoplasia of the stomach: Relationship with p53 status and prolif-
erative activity. J Pathol 180: 122-128, 1996.
36. Czerniak B, Herz F, Gorczyca W and Koss LG: Expression of 
ras oncogene p21 protein in early gastric carcinoma and adjacent 
gastric epithelia. Cancer 164: 1467‑1473, 1989.
37. Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, 
Harada Y, Sugimura T and Terada M: Mutation frequency of the 
p16/CDKN2 gene in primary cancers in the upper digestive tract. 
Cancer Res 55: 3421‑3423, 1995.
38. Ohuchi N, Hand PH, Merlo G, Fujita J, Mariani-Costantini R, 
Thor A, Nose M, Callahan R and Schlom J: Enhanced expression 
of c‑Ha‑ras p21 in human stomach adenocarcinomas defined 
by immunoassays using monoclonal antibodies and in situ 
hybridization. Cancer Res 47: 1413‑1420, 1987.
